Evaluation of a yeast-derived β-1,3/1,6-glucan preparation as a potential immunopotentiator for live La Sota Newcastle disease vaccination in broiler chickens
Letters in Animal Biology · 17.11.2026 · 6 (1) · 239-245
DOI: 10.62310/liab.v6i1.467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Animal Biology, online erschienen am 17.11.2026. Verfasst von Wesam Alqwidi und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Newcastle disease (ND) remains a constraint in vaccinated broiler chicken flocks, and practical immunopotentiators compatible with mass administration warrant evaluation. This exploratory study assessed short courses of a yeast-derived, water-dispersible preparation containing approximately 80% β-1,3/1,6-glucan in broilers receiving a single live La Sota vaccination. Three hundred day-old male Ross 308 chicks were allocated to five groups of 60 birds with four replicate pens per group: unvaccinated control (Control), vaccinated only (Vac), and vaccinated plus glucan at 0.5, 1, or 2 g/L in the drinking water (Vac β-Low, Vac β-Med, and Vac β-High, respectively). Glucan was administered on days 6–10, 21–22, and 28–29; the vaccine was administered by eye drop on day 7. Body weight, relative spleen, bursa, and thymus indices, hemagglutination-inhibition (HI) antibody titers; and 7-day survival following challenge on day 35 were recorded. The growth records showed an implausibly large increase between days 21 and 28 and could not be independently verified from the available data; consequently, the growth findings were presented as descriptive, and no claim of a growth effect or absence of a growth penalty was made. Exploratory organ index comparisons indicated that compared to Vac, Vac β-Med and Vac β-High had higher spleen indices on day 14, whereas only Vac β-High differed significantly from Vac on day 28. The age-wise analysis revealed that day-21 HI titer was higher in the Vac β-Med group than in the Vac group; whereas day-28 titers did not differ significantly. The day 42 samples were obtained from survivors only and therefore cannot be interpreted as an uncomplicated vaccine-response endpoint. The survival rates were 20%, 60%, 70%, 90%, and 80% in the control, Vac, Vac β-Low, Vac β-Med, and Vac β-High groups, respectively. The difference in the survival between Vac β-Med and Vac groups was 30 percentage points (approximate 95% CI: 2 to 52), but the exact odds ratio was imprecise (5.7, 95% CI: 0.9–64.6), and the comparison was not significant after the Holm adjustment (adjusted p = 0.19). Because each treatment was represented by a single challenge unit, bird-level survival comparisons are potentially pseudoreplicated. This study provides an exploratory signal for further testing but does not establish protection, an optimal dose, or an independent immunostimulatory mechanism.
Zitieren
APA
Alqwidi, W., Marzok, M. A., Mohamed, M., El-Sabagh, I., El-Sherif, M., Hafez, M. A., Mohamed, M., & Soliman, M. (2026). Evaluation of a yeast-derived β-1,3/1,6-glucan preparation as a potential immunopotentiator for live La Sota Newcastle disease vaccination in broiler chickens. Letters in Animal Biology, 6(1), 239-245. https://doi.org/10.62310/liab.v6i1.467
Vancouver
Alqwidi W, Marzok MA, Mohamed M, El-Sabagh I, El-Sherif M, Hafez MA, et al. Evaluation of a yeast-derived β-1,3/1,6-glucan preparation as a potential immunopotentiator for live La Sota Newcastle disease vaccination in broiler chickens. Letters in Animal Biology. 2026;6(1):239-245. doi:10.62310/liab.v6i1.467
BibTeX
@article{Alqwidi2026,
author = {Alqwidi, Wesam and Marzok, Mohamed A. and Mohamed, Mahmoud and El-Sabagh, Ibrahim and El-Sherif, Mohamed and Hafez, Mohammed Abdel and Mohamed, Mohamed and Soliman, Mohamed},
title = {Evaluation of a yeast-derived β-1,3/1,6-glucan preparation as a potential immunopotentiator for live La Sota Newcastle disease vaccination in broiler chickens},
journal = {Letters in Animal Biology},
year = {2026},
volume = {6},
number = {1},
pages = {239--245},
doi = {10.62310/liab.v6i1.467}
}
EUVIMED